Sandoz Victoza Settlement Sets Up Face-Off With Teva And Viatris

Novo Nordisk’s cornerstone type 2 diabetes treatment Victoza is set to come under siege from the three largest generics manufacturers beginning in June 2024, after Sandoz became the last of the trio to sign a licensing agreement with the Danish originator that resolves patent-litigation proceedings.